Reports by financial daily Mint has indicated on Friday that a government panel of experts is investigating for domestic cases of blood clotting, even mild ones, as a side effect of the two COVID-19 vaccines being administered in India, citing two people aware of the development.
India, according to reports emanating from the Asian country, is currently administering AstraZeneca’s COVID-19 vaccine, which is manufactured by the Serum Institute and branded Covishield, and a shot developed by Bharat Biotech called COVAXIN.
The review comes after Europe’s drug regulator said, on Wednesday, that it found a possible link between AstraZeneca’s vaccine and rare blood clotting issues in adults who had received the shot, although it added the vaccine’s advantages still outweighed the risks.
India is banking on vaccinations to help contain a record surge in cases in its second wave as the country reported a massive 126,789 new COVID-19 cases on Thursday.
A source told Mint, who added that a report on it was likely to be ready by next week.
The source said:
We are looking at side-effects of blood clots that have been seen in people who received Covishield and Covaxin, even if it was a mild case.
Following Europe’s announcement, several countries have announced restrictions on the use of the AstraZeneca vaccine in younger people.
The move by the Indian government is coming as Hong Kong, on Friday, confirmed it has requested AstraZeneca suspend delivery of its COVID-19 vaccine amid fears of severe side effects and concerns over its efficacy against new variants of the coronavirus.
Europe’s medicines regulator said this week the AstraZeneca vaccine could cause very rare blood clots in some recipients, prompting a cascade of countries to pull the plug on giving it to people under a certain age.
Britain sought Thursday to quell fears over the jab, saying the potential side effects were extremely rare and the risk of falling seriously sick from COVID-19 was far greater.